featured
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study
J. Clin. Oncol 2019 Sep 18;[EPub Ahead of Print], MS Khodadoust, AH Rook, P Porcu, F Foss, AJ Moskowitz, A Shustov, S Shanbhag, L Sokol, SP Fling, N Ramchurren, R Pierce, A Davis, R Shine, S Li, S Fong, J Kim, Y Yang, WM Blumenschein, JH Yearley, B Das, R Patidar, V Datta, E Cantu, JN McCutcheon, C Karlovich, PM Williams, PB Subrahmanyam, HT Maecker, SM Horwitz, E Sharon, HE Kohrt, MA Cheever, YH KimFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.